Top Companies in Middle East Cancer Biomarkers Market with Market Size | Manufacturers & Suppliers 2025

Top Companies in Middle East Cancer Biomarkers Market with Market Size

Middle East Cancer Biomarkers Market has seen significant advancements, driven by the key players who have contributed through innovation and strategic initiatives. The expansion in this sector can be attributed to a focus on research and development, which has led to the introduction of new biomarkers that enhance the accuracy of cancer diagnosis and treatment monitoring.  One notable contribution is the emphasis on developing novel biomarker technologies that enable early detection of various cancer types while reducing overall treatment costs. Such innovations include advancements in genomic and proteomic technologies, which have improved the sensitivity and specificity of cancer biomarkers. Market breakthroughs are crucial for identifying cancer at an earlier stage, which significantly increases the chances of successful treatment and survival.

Furthermore, collaborations and partnerships among pharmaceutical companies, academic institutions, and healthcare organizations have played a pivotal role in advancing the cancer biomarkers market in the Middle East. Market collaborations have facilitated the sharing of knowledge, resources, and expertise, thereby accelerating the development and commercialization of innovative biomarker technologies. The cooperation between public and private sectors has also helped in the establishment of robust healthcare infrastructure, which supports the widespread adoption of cancer biomarker testing across the region.

Another key factor contributing to the market's growth is the increased investment in personalized medicine. By tailoring treatment plans according to individual patient profiles, personalized medicine enhances treatment efficacy and minimizes adverse effects, making it an attractive approach in cancer care. The integration of cancer biomarkers into personalized treatment strategies has gained traction, leading to more targeted and effective therapies. As per 6Wresearch, Middle East Cancer Biomarkers Market is projected to grow at a significant CAGR of 10% from 2025-2031F.

List of Leading Companies in the Middle East Cancer Biomarkers Market

1. Thermo Fisher Scientific

Thermo Fisher Scientific is a global leader in scientific research services, providing analytical instruments, laboratory supplies, and reagents. It has a significant presence in the cancer biomarker field, especially in diagnostics and molecular research. Thermo Fisher Scientific has pioneered various products used in cancer research, including its broad portfolio of biomarker assays and gene expression analysis technologies. The company is particularly recognized for its role in next-generation sequencing (NGS) and liquid biopsy testing, making it a key player in the cancer diagnostics market.

2. Qiagen N.V.

Founded in 1984, Qiagen is a leader in molecular diagnostics and sample preparation technologies, offering a wide range of products for cancer biomarker testing. With its headquarters in Hilden, Germany, Qiagen focuses on providing technologies for DNA, RNA, and protein research. Its products are widely used in clinical diagnostics, research laboratories, and pharmaceutical research, enabling personalized cancer treatments. Qiagen’s flagship products, including the QIAamp and QIAcube systems, facilitate the extraction and purification of nucleic acids, essential for biomarker discovery and validation. 

3. Illumina, Inc.

Illumina, headquartered in San Diego, California, is a global leader in genomics technology, with its NGS platforms driving major advances in cancer biomarker research. Founded in 1998, the company’s high-throughput sequencing systems, like the NovaSeq and MiSeq, have transformed the landscape of cancer genomics by enabling comprehensive profiling of genetic mutations and alterations. Illumina’s technology allows clinicians and researchers to examine genetic changes associated with cancer, offering insights into prognosis, treatment decisions, and potential therapeutic responses. 

4. Roche Diagnostics

Roche is a global pioneer in pharmaceuticals and diagnostics, with a deep commitment to improving healthcare through innovative solutions. Established in 1896, Roche's diagnostics division plays a crucial role in cancer biomarker testing, offering a wide range of diagnostic assays and instruments that enable the detection of cancer at various stages. Roche’s cancer biomarker solutions include its Elecsys and cobas platforms, which are widely used in oncology for testing biomarkers like HER2, EGFR, and ALK. The company’s biomarker tests are used to guide treatment decisions and monitor therapy response. 

5. Abbott Laboratories

Abbott Laboratories, founded in 1888, is an American multinational healthcare company that provides a broad array of medical devices, diagnostics, branded generic medicines, and nutrition products. Abbott is a major player in cancer diagnostics, focusing on assays and instruments that help detect genetic mutations and biomarkers relevant to oncology. In the Middle East, Abbott has established a significant presence with its diagnostic systems that enable early detection of cancer. Its oncology diagnostics offerings are used across hospitals and research centers to identify biomarkers for breast cancer, prostate cancer, and other solid tumors. Abbott's leadership in diagnostic technologies, such as the Alinity system, has helped streamline cancer biomarker testing, making it faster, more reliable, and accessible to patients throughout the region.

6. Agilent Technologies

Agilent's technologies are widely used in cancer genomics, proteomics, and transcriptomics to uncover biomarkers that can lead to earlier diagnosis and more personalized treatments. Their platforms, including the SureSelect target enrichment system and the 1290 Infinity LC system, are key tools for discovering and validating cancer biomarkers. These systems facilitate high-precision genomic analysis and protein expression studies, enabling researchers to identify new cancer-related genetic alterations and biomarkers. In the Middle East, Agilent is a key partner in advancing cancer biomarker research, especially with the increasing focus on precision oncology and personalized medicine. The company is well-positioned in the region, providing tools that help hospitals, research institutions, and pharmaceutical companies improve cancer detection, treatment decision-making, and patient outcomes.

7. Bio-Rad Laboratories

Founded in 1952 and headquartered in Hercules, California, USA, Bio-Rad Laboratories is a global leader in life science research and clinical diagnostics. Bio-Rad’s tools for cancer biomarker testing are crucial for advancing research into cancer pathophysiology and therapy development. Bio-Rad offers a broad range of products, including ELISA kits, PCR reagents, and qPCR systems, which are extensively used in both diagnostic and research settings for detecting cancer biomarkers. Its products help identify biomarkers that predict patient responses to specific cancer treatments, enabling the development of more effective therapies. 

8. Merck & Co., Inc.

Merck & Co., founded in 1891 and headquartered in Kenilworth, New Jersey, USA, is a global healthcare company with a long history in research and development, including oncology. Merck’s cancer immunotherapy products, such as its checkpoint inhibitors (e.g., Keytruda), have revolutionized cancer treatment. Additionally, Merck has significant expertise in developing biomarker assays to predict patient responses to these therapies. Merck’s biomarker discovery platform leverages next-generation sequencing (NGS) to identify genetic mutations and biomarkers that guide treatment decisions for various types of cancer. 

9. Siemens Healthineers

Siemens Healthineers, part of the Siemens Group since 1847, is headquartered in Erlangen, Germany, and specializes in medical technology, including diagnostic imaging and laboratory diagnostics. Siemens has been a pioneer in integrating advanced imaging technologies and diagnostic testing, offering solutions that aid in the early detection of cancer. Siemens Healthineers’ molecular diagnostic instruments, including its ADVIA Centaur and Atellica series, are instrumental in cancer biomarker testing. These systems enable the analysis of blood samples for specific cancer markers such as prostate-specific antigen (PSA) and CA-125, which are used to monitor cancer progression and treatment effectiveness. In the Middle East, Siemens Healthineers plays a critical role in the development of diagnostic infrastructure, providing hospitals and clinics with tools to diagnose and monitor cancers effectively.

10. Becton, Dickinson and Company (BD)

BD, established in 1897 and headquartered in Franklin Lakes, New Jersey, USA, is a leading global medical technology company. BD’s innovative diagnostic solutions include systems for cancer biomarker testing, such as its BD FACSCanto™ flow cytometer, which is used to assess biomarker expression in cancer cells. BD’s technologies are used to detect and monitor various cancer biomarkers, particularly in hematological cancers like leukemia and lymphoma. Their diagnostic platforms provide clinicians with the necessary tools to conduct detailed biomarker analysis, offering insights into tumor behavior and treatment responses. 

11. SAB Biotherapeutics

Founded in 2014 and based in Sioux Falls, South Dakota, USA, SAB Biotherapeutics is a biotechnology company specializing in the development of immunotherapies and precision medicine for cancer treatment. While still a relatively young company, SAB Biotherapeutics has made significant strides in leveraging its proprietary technology for the production of fully human antibodies that can target specific cancer biomarkers. SAB’s innovative platform is based on the use of genetically engineered animals to produce human antibodies, which are then used to treat a wide range of diseases, including cancer. In particular, SAB is focusing on cancer immunotherapy, where tumor-specific biomarkers are targeted for more effective and less toxic treatments. 

12. PerkinElmer, Inc.

PerkinElmer, founded in 1937 and headquartered in Waltham, Massachusetts, USA, is a major player in the life sciences, diagnostics, and environmental health sectors. The company’s cancer biomarker solutions range from genetic testing to imaging technologies, providing essential tools for early cancer detection and therapy monitoring. PerkinElmer’s diagnostic platforms and reagents are used globally for identifying genetic mutations and biomarkers associated with various cancers. In particular, their BioMarker and NGS solutions have significantly enhanced the ability to perform personalized cancer treatments and clinical trials.

Frequently Asked Questions About the Market Study (FAQs):